Introduction {#jde12971-sec-0001}
============

Urticaria is one of the most common skin diseases and is characterized by the appearance of itchy wheals and flares that usually disappear within hours.[1](#jde12971-bib-0001){ref-type="ref"} "Spontaneous urticaria" is the most common type, in which wheals develop spontaneously over the course of a day. It consists of acute (spontaneous) urticaria and chronic (spontaneous) urticaria, in which wheals occur for less than 6 weeks or 6 weeks or more, respectively.[2](#jde12971-bib-0002){ref-type="ref"} In Japan, the term "chronic urticaria" is used to represent, on some occasions, urticaria that continues for more than 1 month regardless of the presence of triggers.[1](#jde12971-bib-0001){ref-type="ref"}

The medication adherence of patients with acute urticaria does not seem to affect the outcome, because it is usually self‐limiting. However, in chronic urticaria, poor adherence often results in the failure of treatment and the relapse of symptoms. Recently, an eight‐item self‐reporting scale was developed by Morisky *et al*.,[3](#jde12971-bib-0003){ref-type="ref"} called the Morisky Medication Adherence Scale‐8 (MMAS‐8). Although this scale originally targeted oral medication for hypertensive patients, we recently assessed the medication adherence for oral and topical remedies using a translated Japanese version of MMAS‐8.[4](#jde12971-bib-0004){ref-type="ref"}, [5](#jde12971-bib-0005){ref-type="ref"} We also performed a subanalysis of 751 registered patients with urticaria in this study.

Methods {#jde12971-sec-0002}
=======

This study was conducted among patients registered in a monitoring system established by Macromill (Tokyo, Japan) which has been described elsewhere.[4](#jde12971-bib-0004){ref-type="ref"}, [5](#jde12971-bib-0005){ref-type="ref"} Our Web‐based questionnaire included questions on the following items: age, sex, marital status, annual income, employment status, educational status, smoking habit, alcohol consumption, frequency of hospital visits, disease duration, main health‐care institution, oral or topical medication, experience of the effectiveness of oral medication, experience of the effectiveness of topical medication, experience of adverse events associated with oral medication, experience of adverse events associated with topical medication and overall satisfaction with treatment, as well as MMAS‐8 for oral medication and MMAS‐8 for topical medication.

The characteristics of the whole sample and of the groups with different levels of adherence in terms of the MMAS‐8 score are presented. The χ^2^‐test for categorical variables or [anova]{.smallcaps} for continuous variables was used to evaluate the differences in the study variables among the three adherence groups. Internal consistency was assessed using Cronbach\'s alpha. An acceptable Cronbach\'s alpha value is considered to be 0.7 or more.[6](#jde12971-bib-0006){ref-type="ref"} Known group validity was assessed through the association of items and MMAS categories using correlation coefficient and covariance. All analyses were performed using STATA version 9 (StataCorp, College Station, TX, USA). The significance level was set at *P* \< 0.05.

Results {#jde12971-sec-0003}
=======

Demographic data of the 751 patients with urticaria are summarized in Table [1](#jde12971-tbl-0001){ref-type="table-wrap"}. The mean age of these subjects was 45.4 years (range, 17--80) and 33.6% of them were male. Among these 751 patients, a total of 673 took oral medication and 528 were treated with topical medication. Mean adherence scores by MMAS‐8 were 4.9 for oral and 4.2 for topical medication. The reliability scores (i.e. Cronbach\'s alpha) were 0.683 for oral MMAS‐8 and 0.726 for topical MMAS‐8, which demonstrated moderate to high reliability of the Japanese version of MMAS‐8.

###### 

Basic characteristics of urticaria patients (*n* = 751)

  Characteristics                          *n*                   \%
  ---------------------------------------- --------------------- ------
  Age, mean (SD, range), years             45.4 (11.7, 17--80)   
  Sex                                                            
  Male                                     252                   33.6
  Female                                   499                   66.4
  Marital status                                                 
  Married                                  270                   36.0
  Unmarried                                481                   64.0
  Annual income                                                  
  ≥¥6 million                              266                   40.6
  \<¥6 million                             389                   59.4
  Employment                                                     
  Employed                                 453                   62.8
  Unemployed                               268                   37.2
  Education                                                      
  University graduate                      306                   41.1
  Not university graduate                  439                   58.9
  Smoking                                                        
  Smoker                                   147                   19.7
  Non‐smoker                               600                   80.3
  Alcohol                                                        
  ≥Once a month                            430                   57.6
  \<Once a month                           317                   42.4
  Frequency of MD visits                                         
  ≥Once a half‐year                        637                   84.8
  \<Once a half‐year or unknown            114                   15.2
  Disease duration                                               
  \<Half a year                            179                   23.8
  ≥Half a year to 1 year                   169                   22.5
  \>1--3 years                             168                   22.4
  \>3--5 years                             71                    9.5
  \>5--10 years                            79                    10.5
  \>10--20 years                           45                    6.0
  \>20 years                               40                    5.3
  Main health‐care institution                                   
  University hospital                      25                    3.4
  Municipal hospital                       135                   18.1
  Private clinic or other                  586                   78.6
  Oral medication                                                
  Experience of drug effectiveness                               
  Yes                                      611                   90.8
  No                                       62                    9.2
  Experience of adverse events                                   
  Yes                                      124                   18.4
  No                                       549                   81.6
  Topical medication                                             
  Experience of drug effectiveness                               
  Yes                                      443                   83.9
  No                                       85                    16.1
  Experience of adverse events                                   
  Yes                                      51                    9.7
  No                                       477                   90.3
  Overall satisfaction with treatment                            
  \>Satisfied                              440                   58.6
  \<Satisfied                              311                   41.4
  Adherence, mean (SD, range)                                    
  Oral medication                          4.9 (1.9, 0.25--8)    
  Topical medication                       4.2 (2.1, 0--8)       
  Cronbach\'s alpha of adherence measure                         
  Oral medication                          0.683                 
  Topical medication                       0.726                 

SD, standard deviation.
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As shown in Table [2](#jde12971-tbl-0002){ref-type="table-wrap"}, the adherence to oral medication was significantly associated with the frequency of hospital visits. Variables that affected the adherence to topical medication were age, disease duration and experience of drug effectiveness.

###### 

Prevalence of study variables for the three adherence levels among urticaria patients: oral and topical medication

  Characteristics                       Oral medication (*n* = 673)   Topical medication (*n* = 528)                                                                                                          
  ------------------------------------- ----------------------------- -------------------------------- ------------- ---------------------------------------------- ------------- ------------- ------------- ----------------------------------------------
  Age, mean (SD), years                 47.7 (10.8)                   46.0 (11.2)                      45.0 (12.1)   0.194                                          48.6 (11.2)   47.8 (12.4)   44.9 (12.3)   0.041
  Sex                                                                                                                                                                                                         
  Male                                  23 (10.3)                     57 (25.5)                        144 (64.3)    0.792                                          8 (4.6)       35 (20.1)     131 (75.3)    0.458
  Female                                39 (8.7)                      114 (25.4)                       296 (65.9)    25 (7.1)                                       62 (17.5)     267 (75.4)                  
  Marital status                                                                                                                                                                                              
  Married                               18 (7.4)                      60 (24.6)                        166 (68.0)    0.384                                          10 (5.1)      37 (18.9)     149 (76.0)    0.698
  Unmarried                             44 (10.3)                     111 (25.9)                       274 (63.9)    23 (6.9)                                       60 (18.1)     249 (75.0)                  
  Annual income                                                                                                                                                                                               
  ≥¥6 million                           26 (11.0)                     60 (25.4)                        150 (63.6)    0.591                                          12 (6.7)      33 (18.5)     133 (74.7)    0.836
  \<¥6 million                          30 (8.5)                      91 (25.8)                        232 (65.7)    16 (5.7)                                       49 (17.4)     217 (77.0)                  
  Employment                                                                                                                                                                                                  
  Employed                              33 (8.0)                      107 (26.1)                       270 (65.9)    0.348                                          15 (4.8)      60 (19.3)     236 (75.9)    0.100
  Unemployed                            27 (11.5)                     60 (25.5)                        148 (63.0)    18 (9.2)                                       30 (15.4)     147 (75.4)                  
  Education                                                                                                                                                                                                   
  University graduate                   22 (7.9)                      74 (26.6)                        182 (65.5)    0.616                                          12 (5.6)      44 (20.4)     160 (74.1)    0.536
  Not university graduate               39 (10.0)                     97 (24.9)                        254 (65.1)    21 (6.8)                                       52 (16.9)     235 (76.3)                  
  Smoking                                                                                                                                                                                                     
  Smoker                                10 (7.8)                      33 (25.8)                        85 (66.4)     0.822                                          6 (5.4)       22 (19.6)     84 (75.0)     0.861
  Non‐smoker                            52 (9.6)                      138 (25.5)                       352 (64.9)    27 (6.6)                                       75 (18.2)     310 (75.2)                  
  Alcohol                                                                                                                                                                                                     
  ≥Once a month                         33 (8.6)                      87 (22.8)                        262 (68.6)    0.104                                          18 (5.9)      49 (16.1)     238 (78.0)    0.190
  \<Once a month                        29 (10.1)                     84 (29.2)                        175 (60.8)    15 (6.8)                                       48 (21.9)     156 (71.2)                  
  Frequency of hospital visits                                                                                                                                                                                
  ≥Once a half‐year                     60 (10.3)                     136 (23.4)                       386 (66.3)    0.001                                          29 (6.6)      76 (17.2)     336 (76.2)    0.276
  \<Once a half‐year or unknown         2 (2.2)                       35 (38.5)                        54 (59.3)     4 (4.6)                                        21 (24.1)     62 (71.3)                   
  Disease duration                                                                                                                                                                                            
  \<Half a year                         16 (10.3)                     47 (30.1)                        93 (59.6)     0.311                                          17 (11.5)     28 (18.9)     103 (69.6)    0.017
  ≥Half a year to 1 year                8 (5.8)                       40 (29.0)                        90 (65.2)     4 (3.1)                                        28 (21.4)     99 (75.6)                   
  \>1--3 years                          15 (9.4)                      36 (22.6)                        108 (67.9)    6 (5.4)                                        24 (21.6)     81 (73.0)                   
  \>3 years                             23 (10.5)                     48 (21.8)                        149 (67.7)    6 (4.4)                                        17 (12.3)     115 (83.3)                  
  Main health‐care institution                                                                                                                                                                                
  University hospital                   3 (13.0)                      5 (21.7)                         15 (65.2)     0.859[a](#jde12971-note-0002){ref-type="fn"}   0 (0.0)       5 (29.4)      12 (70.6)     0.474[a](#jde12971-note-0002){ref-type="fn"}
  Municipal hospital                    10 (8.6)                      27 (23.1)                        80 (68.4)     6 (6.5)                                        20 (21.5)     67 (72.0)                   
  Private clinic or other               48 (9.1)                      139 (26.2)                       343 (64.7)    27 (6.5)                                       69 (16.6)     319 (76.9)                  
  Experience of drug effectiveness                                                                                                                                                                            
  Yes                                   58 (9.5)                      157 (25.7)                       396 (64.8)    0.575                                          30 (6.8)      88 (19.9)     325 (73.4)    0.049
  No                                    4 (6.5)                       14 (22.6)                        44 (71.0)     3 (3.5)                                        9 (10.6)      73 (85.9)                   
  Experience of adverse events                                                                                                                                                                                
  Yes                                   10 (8.1)                      32 (25.8)                        82 (66.1)     0.887                                          2 (3.9)       10 (19.6)     39 (76.5)     0.864[a](#jde12971-note-0002){ref-type="fn"}
  No                                    52 (9.5)                      139 (25.3)                       358 (65.2)    31 (6.5)                                       87 (18.2)     359 (75.3)                  
  Overall satisfaction with treatment                                                                                                                                                                         
  \>Satisfied                           37 (9.4)                      109 (27.8)                       246 (62.8)    0.205                                          22 (7.0)      60 (19.1)     232 (73.9)    0.558
  \<Satisfied                           25 (8.9)                      62 (22.1)                        194 (69.0)    11 (5.1)                                       37 (17.3)     166 (77.6)                  

Fisher\'s exact test. SD, standard deviation.
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Among the 673 urticaria patients with oral drugs, 75 (11.1%) admitted that they ignored doctors' instructions, whereas 124 of the 528 (23.5%) urticaria patients with topical remedies did so. Although 29.0% (36/124) of patients stopped applying topical remedies because they thought their lesion had been cured, significantly more patients (48.0%; 36/75) stopped oral drugs due to the same reason, suggesting that the adherence to oral drugs could be affected more by patients' own decisions regarding continued medication use (Table [3](#jde12971-tbl-0003){ref-type="table-wrap"}). Factors that influence adherence to oral and topical medication were investigated. Patients' reasons for not adhering to their doctors' instructions were explored. As shown in Table [3](#jde12971-tbl-0003){ref-type="table-wrap"}, the rate of responses that "It felt like the symptoms had improved" varied significantly among the four skin diseases treated with oral medications. There was no significant difference in the rates of patient adherence to topical treatment plans among the four diseases.

###### 

Factors that influence poor adherence to oral and topical medication

  Oral medication                          Atopic dermatitis, *n* = 177 (61.9%)   Urticaria, *n* = 75 (26.2%)   Psoriasis, *n* = 13 (4.5%)   Tinea, *n* = 21 (7.3%)   *P*
  ---------------------------------------- -------------------------------------- ----------------------------- ---------------------------- ------------------------ -------
  It felt like the symptoms had improved                                                                                                                              
  Yes                                      69 (39.0)                              36 (48.0)                     4 (30.8)                     2 (9.5)                  0.009
  No                                       108 (61.0)                             39 (52.0)                     9 (69.2)                     19 (90.5)                

  Topical medication                       Atopic dermatitis, *n* = 349 (50.7%)   Urticaria, *n* = 124 (18.0%)   Psoriasis, *n* = 73 (10.6%)   Tinea, *n* = 143 (20.8%)   *P*
  ---------------------------------------- -------------------------------------- ------------------------------ ----------------------------- -------------------------- -------
  It felt like the symptoms had improved                                                                                                                                  
  Yes                                      122 (35.0)                             36 (29.0)                      24 (32.9)                     45 (31.5)                  0.650
  No                                       227 (65.0)                             88 (71.0)                      49 (67.1)                     98 (68.5)                  
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Discussion {#jde12971-sec-0004}
==========

Demographic data showed that at least 76.2% of patients suffered from chronic urticaria (for half a year or longer, Table [1](#jde12971-tbl-0001){ref-type="table-wrap"}), although the subtypes of urticaria (e.g. spontaneous or inducible) were unknown. Previous reports showed that approximately 70% of patients with urticaria suffered from the spontaneous type.[7](#jde12971-bib-0007){ref-type="ref"}, [8](#jde12971-bib-0008){ref-type="ref"} Therefore, at least half of the patients with urticaria in this survey could be classified as having chronic spontaneous urticaria. The proportion of female patients (66.4%) was approximately double that of the male ones (33.6%). In addition, the percentage of patients aged in their 30s to 50s, in the prime of life, was 82.3%. These demographic data are compatible with previous investigations on chronic urticaria.[9](#jde12971-bib-0009){ref-type="ref"}, [10](#jde12971-bib-0010){ref-type="ref"}

In our Web‐based questionnaires, the patients were asked whether or not they had received medical treatment at a medical institution in the past year. The patients who answered that they had received medical treatment for atopic dermatitis, urticaria, psoriasis or tinea were asked the following additional question: "How much time has passed since you were diagnosed with that skin disease?". Thus, patients who answered this question might have included patients with acute urticaria. Because the symptom of acute urticaria resolves in a short time, these patients have fewer adherence‐related problems, and may have better adherence to medication. Actually, in topical medication, patients with a disease duration of less than 6 months demonstrated significantly better adherence. However, in oral medication, no significant difference was observed in adherence between patients with different disease durations. This implies that patients with urticaria who require oral medication have poor adherence to medication irrespective of disease duration. In future study, we believe that we need to perform specific selection of patients with chronic spontaneous urticaria, in whom poor adherence is often observed (Table [2](#jde12971-tbl-0002){ref-type="table-wrap"}).

Adherence refers to patients actively participating in the therapeutic decision‐making process and being treated accordingly.[11](#jde12971-bib-0011){ref-type="ref"} Improving adherence via patient--doctor communication is essential for proper treatment. Common causes of poor adherence include a high frequency of medication administration, denial of the existence of an illness, a lack of understanding of the benefits of medication and cost.[12](#jde12971-bib-0012){ref-type="ref"} In Europe, treatment in accordance with guidelines improved adherence, so the early application of guideline‐based chronic urticaria management may be a cost‐effective way to improve outcomes.[13](#jde12971-bib-0013){ref-type="ref"}

For urticaria, the dose of oral medication (antihistamines) required for remission is dependent on the individual. Interminable treatment may lead to poor adherence. Among the four groups of dermatology patients (atopic dermatitis, urticaria, psoriasis and tinea), those with urticaria showed the poorest adherence, followed by those with atopic dermatitis.[4](#jde12971-bib-0004){ref-type="ref"} Compared with patients with hypertension and diabetes, with whom comparative studies were conducted, patients with urticaria showed poorer adherence.[3](#jde12971-bib-0003){ref-type="ref"}, [14](#jde12971-bib-0014){ref-type="ref"} The reasons for such poor adherence are believed to be as follows: symptoms with fluctuating severity, the ease with which patients can stop treatment by themselves and low disease severity (not life‐threatening). Although advances in Japanese health care have made treatment accessible at any time at low cost, atopic dermatitis and urticaria are diseases that significantly impair the quality of life of patients,[15](#jde12971-bib-0015){ref-type="ref"} so poor adherence should not be ignored.

In conclusion, to improve adherence to urticaria treatment, patients should be aware of the importance of continuing oral medication for a certain period proactively, even if they do not have any symptoms. Concurrently, evidence is needed to show how long patients should continue oral medications depending on the severity and duration of urticaria. Furthermore, the evidence‐based treatment guidelines for urticaria should be widely accepted by not only dermatologists, but also primary physicians.
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